Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4

11 Feb 2019

Abstract excerpt

To understand immunomodulatory drug (IMiD) resistance in multiple myeloma (MM), we created isogenic human multiple myeloma cell lines (HMCLs) sensitive and resistant to lenalidomide, respectively. Four HMCLs were demonstrated to be resistant to all IMiDs including lenalidomide, pomalidomide, and CC-220, but not to Bortezomib. In three HMLCs (MM.1.SLenRes, KMS11LenRes and OPM2LenRes), CRBN abnormalities were...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Histone Deacetylase Inhibitors Research
Share to Multiple Myeloma Research and Treatments
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30741931
DOI: 10.1038/s41408-019-0173-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4PMID 30741931Read ↗

Cereblon loss and up-regulation of c-Myc are associated with lenalidomide resistance in multiple myeloma patientsSemantic proximity Read ↗

Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myelomaSemantic proximity Read ↗

Small-molecule HDAC and Akt Inhibitors Suppress Tumor Growth and Enhance Immunotherapy in Multiple MyelomaSemantic proximity Read ↗

IMiD Resistance in Multiple Myeloma: Current Understanding of the Underpinning Biology and Clinical ImpactSemantic proximity Read ↗

MYC Inhibition Potentiates CD8+ T Cells Against Multiple Myeloma and Overcomes Immunomodulatory Drug ResistanceSemantic proximity Read ↗

Tumor and microenvironmental mechanisms of resistance to immunomodulatory drugs in multiple myelomaSemantic proximity Read ↗

Expression, mutation, and methylation of cereblon-pathway genes at pre- and post-lenalidomide treatment in multiple myeloma.Semantic proximity Read ↗

RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradationSemantic proximity Read ↗

RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradationSemantic proximity Read ↗

Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon‐independent mannerSemantic proximity Read ↗

Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma.Semantic proximity Read ↗

Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomideSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.